The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction

Recruiting N/A Interventional Study
Heart Failure With Preserved Ejection Fraction Obesity
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 85
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
120 (estimated)
Sponsor
University of Oxford · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study looks at the effects of weight loss in people who have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese. The main questions it aims to answer are whether weight loss in this group of people improves: 1. The heart's shape, how well it pumps blood and how well it uses fuels 2. The person's quality of life and how much they can exercise Participants wil…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Heart failure with preserved ejection fraction (HFpEF) * Left ventricular ejection fraction (LVEF) =/\> 50% * Body Mass Index (BMI) approximately =/\> 27.5 kg/m\^2 Exclusion Criteria: * Contraindications to magnetic resonance imaging * NYHA class IV * Significant valvular, i…
Contacts

Jiliu Pan, BMBCh

+44(0)1865234591

jiliu.pan@cardiov.ox.ac.uk

CONTACT

Jenny Rayner, DPhil

+44(0)1865221172

jenny.rayner@cardiov.ox.ac.uk

CONTACT